ROOTS: A multicenter study in Belgium to evaluate the effectiveness and safety of liraglutide (Victoza®) in type 2 diabetic patients

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 9, Issue 3, 2015, Pages 139-142

  Buysschaert, Martin ^a   D'Hooge, Dirk ^b   Preumont, Vanessa ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Adverse drug reactions; Dosage; HbA1c; Liraglutide; Type 2 diabetes; Weight

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; BELGIUM; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; AGED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL;

AGED; BELGIUM; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; METFORMIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 84937513173     PISSN: 18714021     EISSN: 18780334     Source Type: Journal    
DOI: 10.1016/j.dsx.2015.05.001     Document Type: Article

References (19)

1. American Diabetes Association Standards of medical care in diabetes - 2014 Diabetes Care 37 Suppl. 1 2014 S14 S80
2. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck, and et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the study of diabetes (EASD) Diabetes Care 35 6 2012 1364 1379
3. M.K. Ali, K.M. Bullard, J.B. Saaddine, C.C. Cowie, G. Imperatore, and E.W. Gregg Achievement of goals in US diabetes care, 1999-2010 N Engl J Med 369 6 2013 587
4. M. Buysschaert, V. Preumont, P.R. Oriot, I. Paris, M. Ponchon, D. Scarniere, and et al. for the UCL Study Group for Exenatide. One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice Diabetes Metab 36 2010 381 388
5. J.J. Meier GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus Nat Rev Endocrinol 8 2012 728 742
6. T. Vilsbøll, M. Zdravkovic, T. Le-Thin, T. Krarup, O. Schmitz, J.P. Courrèges, and et al. Liraglutide, a long-acting glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycaemia in patients with type 2 diabetes Diabetes Care 30 2007 1608 1610
7. ®): place d'un nouvel analogue du GLP-1 dans le traitement du diabète de type 2 Louvain Med 129 8 2010 296 301
8. M. Marre, J. Shaw, M. Brändle, W.M.W. Bebakar, N.A. Kamaruddin, J. Strand, and et al. Treatment liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU) Diabetic Med 26 2009 268 278
9. M. Nauck, A. Frid, K. Hermansen, N.S. Shah, T. Tankova, I.H. Mitha, and et al. Effi cacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes. The LEAD (Liraglutide Effect and Action in Diabetes)-2 study Diabetes Care 32 2009 84 90
10. A. Garber, R. Henry, R. Ratner, P.A. Garcia-Hernandez, H. Rodriguez-Pattzi, I. Olvera-Alvarez, and et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial Lancet 373 2009 473 481
11. B. Zinman, J. Gerich, J.B. Buse, A. Lewin, S. Schwartz, Raskin Ph, and et al. Effi cacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD) Diabetes Care 32 2009 1224 1230
12. D. Russell-Jones, A. Vaag, O. Schmitz, B.K. Sethi, N. Lalic, S. Antic, and et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial Diabetologia 52 2009 2046 2055
13. Workgroup on Hypoglycemia American Diabetes Association: Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on hypoglycemia Diabetes Care 28 2005 1245 1249
14. J.B. Buse, J. Rosenstock, G. Sesti, W.E. Schmidt, E. Montanya, J.H. Brett, and et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD 6) Lancet 374 2009 39 47
15. C. Kapitza, T. Forst, H.V. Coester, F. Poitiers, P. Ruus, and A. Hincelin-Méry Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin Diabetes Obes Metab 15 2013 642 649
16. J.B. Buse, M. Nauck, T. Forst, W.H.H. Sheu, S.K. Shenouda, C.R. Heilmann, and et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6: a randomized, open- label study Lancet 381 2013 117 124
17. R.E. Pratley, M. Nauck, A.H. Barnett, and et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study Lancet Diabetes Endocrinol 2 2014 289 297
18. A.G. Egan, E. Blind, K. Dunder, P.A. de Graeff, B.T. Hummer, T. Bourcier, and et al. Pancreatic safety of incretin-based drugs - FDA and EMA assessment N Engl J Med 370 2014 794 797
19. P. Gourdy, A. Penfornis, G. Charpentier, S. Madani, L. Martinez, E. Eschwège, and et al. Effectiveness and tolerability with liraglutide among patients with type 2 diabetes. 1-year data from EVIDENCE: a 2-year, prospective, follow up, post-marketing study Diabetologia 56 Suppl. 1 2013 S369 [Abstract 923]